Gene Polymorphism in Tinea Versicolor

• Conditions: Recurrent Pityriasis Versicolor

• Registration Number: NCT04769804
• Lead Sponsor: Kasr El Aini Hospital

Brief Summary

Blood samples will be taken from cases presenting with recurrent tinea versicolor , after confirmation of diagnosis by wood's light and KOH examination, for the detection of gene polymorphism in IL17 A and IL17 F.

In addition , serum samples from patients and controls will be tested for 25(OH)2 D3

Detailed Description

Not available

Study Timeline

• Study Start: 2019-11-01
• Status Verified: 2021-02
• Study First Submitted: 2021-02-21
• Study First Submitted QC: 2021-02-21
• Study First Posted: 2021-02-25
• Last Update Submitted: 2021-04-22
• Last Update Posted: 2021-04-26
• Primary Completion: 2021-06-01
• Study Completion: 2021-11-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• • Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
• Patients of both genders.
• Age ≥18 years old.

Exclusion Criteria

• • Patients with other cutaneous diseases.
• Patient's having dandruff (scaly scalp) even if not symptomatizing.
• Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
• Patients with autoimmune diseases.
• Patients with immunodeficiency diseases.
• Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IL 17A gene polymorphism	6months-1 year	IL 17A
IL 17 F gene polymorphism	6months-1 year	IL 17 F

Secondary Outcome Measures

Name	Time	Method
Vitamin D	6months-1 year	Serum 25(OH)2 D3

Trial Locations

Locations (1)

Kasr Al Ainy Hospital, Cairo university; 🇪🇬 Cairo, El Manial, Egypt